The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...

After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left scrambling to figure out what to do.

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...

The shortage of popular diabetes and weight-loss drugs known as GLP-1s — and insurers’ uneven coverage of them — is putting an unprecedented supply of compounded drugs in consumers' medicine cabinets.